Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Peer-Reviewed Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Tmem14aem1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Tmem14aem1flox/Cya

Common Name
Tmem14a-flox
Product ID
S-CKO-16308
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-75712-Tmem14a-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Tmem14a-flox Mouse (Catalog S-CKO-16308) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Tmem14a-flox
Strain ID
CKOCMP-75712-Tmem14a-B6J-VA
Gene Name
Tmem14a
Product ID
S-CKO-16308
Gene Alias
PTD011, 5730496E24Rik
Background
C57BL/6JCya
NCBI ID
75712 (Mouse)
Modification
Conditional knockout
Chromosome
Chr 1 (Mouse)
Phenotype
MGI:1922962
Datasheet
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000027064
NCBI Transcript ID
NM_001290679
Target Region
Exon 4
Size of Effective Region
~1.8 kb
Overview of Gene Research
Tmem14a, a transmembrane protein, has been implicated in multiple biological processes. It contains a putative transmembrane domain and is an integral transmembrane protein of 99 amino acids with three transmembrane domains [3,4]. While its exact function is still being elucidated, studies suggest it may play roles in apoptosis regulation, cell proliferation, and energy metabolism, and is associated with maintaining the integrity of the glomerular filtration barrier [3,4].

In ovarian cancer, Tmem14a is highly expressed and is correlated with prognostic conditions. It inhibits cell apoptosis, accelerates energy metabolism like glycolysis and oxygen respiration, and is positively correlated with c-Myc. Overexpression of c-Myc can rescue its function, indicating its potential as a diagnostic and prognostic biomarker and a molecular target for therapy [1].

In non-small-cell lung cancer (NSCLC), AXL transcriptionally up-regulates Tmem14a expression to mediate cell proliferation. Silencing Tmem14a reduces cellular proliferation and ATP levels, suggesting it could be a therapeutic target for NSCLC patients undergoing AXL-targeted therapies [2].

In human ovarian cancer cells, knockdown of Tmem14a by RNAi reduces cell proliferation, causes cell cycle arrest, suppresses cell invasion, and down-regulates related proteins and the phosphorylation of Smad2 and Smad3 in the TGF-β signalling pathway, indicating a pro-tumorigenic effect [5].

In zebrafish embryos, knocking down tmem14a mRNA translation results in proteinuria, suggesting its role in maintaining glomerular filtration barrier integrity [4].

In conclusion, Tmem14a is involved in various biological processes, especially in cancer-related events such as cell apoptosis, proliferation, and invasion. Its role in maintaining the integrity of the glomerular filtration barrier is also significant. Functional studies, including those using gene knockdown models, have provided insights into its functions in specific disease conditions, highlighting its potential as a biomarker and therapeutic target in ovarian cancer and NSCLC [1,2,4,5].

References:
1. Zhang, Qingmei, Wang, Xiaohong, Zhang, Xuan, Jia, Jin, Chen, Jie. 2022. TMEM14A aggravates the progression of human ovarian cancer cells by enhancing the activity of glycolysis. In Experimental and therapeutic medicine, 24, 614. doi:10.3892/etm.2022.11551. https://pubmed.ncbi.nlm.nih.gov/36160886/
2. Jang, Te-Hsuan, Lin, Sheng-Chieh, Yang, Ya-Yu, Kuo, Tsu-Hsiang, Chuang, Shuang-En. 2023. AXL transcriptionally up-regulates TMEM14A expression to mediate cell proliferation in non-small-cell lung cancer cells. In Biochemical and biophysical research communications, 682, 365-370. doi:10.1016/j.bbrc.2023.10.027. https://pubmed.ncbi.nlm.nih.gov/37839105/
3. Woo, Im Sun, Jin, Hana, Kang, Eun Sil, Choi, Wan Sung, Seo, Han Geuk. 2011. TMEM14A inhibits N-(4-hydroxyphenyl)retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential. In Cancer letters, 309, 190-8. doi:10.1016/j.canlet.2011.05.031. https://pubmed.ncbi.nlm.nih.gov/21723035/
4. Khalil, Ramzi, Bonnemaijer, Josephine D D, Kreutz, Reinhold, Hogendoorn, Pancras C W, Baelde, Hans J. . Transmembrane protein 14A protects glomerular filtration barrier integrity. In Physiological reports, 11, e15847. doi:10.14814/phy2.15847. https://pubmed.ncbi.nlm.nih.gov/38054547/
5. Zhang, Qingmei, Chen, Xiufeng, Zhang, Xuan, Zhan, Jingfen, Chen, Jie. 2016. Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells. In Bioscience reports, 36, e00298. doi:10.1042/BSR20150258. https://pubmed.ncbi.nlm.nih.gov/26896463/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research